- Microdosing surveys consistently show mood improvement at 4-6 weeks. The Hutten 2024 placebo-controlled LSD microdose trial found no significant antidepressant effect vs placebo in healthy adults.
- The Szigeti 2021 self-blinded RCT (n=191) found microdosing’s mood benefit matched the placebo response — strong evidence the effect is largely expectancy.
- For diagnosed depression, full-dose psilocybin protocols win: the COMPASS Phase 2b (Goodwin 2022, NEJM, n=233) showed strong efficacy in TRD. See our dedicated TRD page.
- Microdosing is plausible as a complement to therapy and lifestyle changes, not a depression treatment in its own right.
- If you are on an SSRI, see SSRI + psilocybin before changing anything.
Depression, in plain terms
Major depressive disorder (MDD) is defined by persistent low mood, loss of interest, and several somatic and cognitive symptoms (sleep, appetite, energy, concentration, worthlessness, suicidality) lasting at least two weeks. Around 7% of adults experience MDD in a given year.
“Microdosing for depression” usually means mild to moderate, often comorbid with anxiety. Severe and treatment-resistant cases are a different question; see our treatment-resistant depression page and microdose vs macrodose comparison.
Standard care, briefly
SSRI/SNRI as first line, CBT or interpersonal therapy alongside, exercise as adjuvant (effect size comparable to medication for mild-moderate cases). About half of patients reach remission on first-line treatment. The rest are why this whole library exists.
Mechanism on depression circuits
- 5-HT2A activation in cortex correlates with reduced default-mode network rigidity. The depressive narrative loosens during the dose. Whether sub-perceptual microdose produces enough of this effect to matter is unclear.
- Neuroplasticity window. Olson lab data shows BDNF and dendritic spine density rise after psilocin and LSD exposure. Microdose-level effect on plasticity is not characterized in vivo.
- Mood through serotonin tone. Indirect, possibly the most relevant for microdose-level effects.
The mechanism does not look like an SSRI mechanism. SSRIs raise synaptic serotonin chronically. Psychedelics produce a brief activation window. Different time courses, different therapeutic logic.
Microdose vs full-dose: the evidence diverges
| Study | Year | Design | Finding |
|---|---|---|---|
| Polito & Stevenson, microdose survey | 2019 | Open-label, n≈98 | Self-reported mood improvement at 6 weeks |
| Hutten et al., Maastricht LSD microdose | 2024 | Placebo-controlled, healthy adults | No significant mood effect vs placebo |
| Szigeti et al., self-blinded RCT, eLife | 2021 | n=191, citizen-science RCT | Microdosing benefit matched placebo response |
| Goodwin et al., COMPASS Phase 2b (full dose) | 2022 | n=233 TRD, 1× 25 mg | Significant MADRS reduction at week 3, sustained at week 12 |
| Davis et al., JHU MDD (full dose) | 2020 | RCT, n=27, 2× 20-30 mg | 71% response, 54% remission at 4 weeks |
| Microdosing for diagnosed MDD placebo-controlled RCT | — | — | None published to date |
Observed protocols
Fadiman: Originally for LSD: 10-20 µg, day on, two days off, then day on again. Adapted to psilocybin: ~0.1 g dried at the same cadence for 4-8 weeks, then a 2-week pause. Fadiman himself noted this is a starting point for 1-2 months, not a fixed framework for everyone.- Stamets stack: 0.1 g psilocybin + lion’s mane + niacin, four days on, three days off.
Fadiman:
Stamets stack:For depression specifically, run alongside therapy and movement (the strongest non-pharmacological antidepressants). Track sleep, mood (PHQ-9 weekly), and energy. Without objective tracking the placebo question is unanswerable for yourself.
Do not microdose if you have any of:
Bipolar I or first-degree family history · Personal or family history of schizophrenia spectrum · Currently taking lithium · Currently on MAOIs · Pregnancy · Active suicidality · Current SSRI without supervised plan (see SSRI page) · Severe cardiovascular disease.
Risks specific to depressed populations
- Suicidality during washout. If you taper an SSRI to microdose, watch for rebound. Plan with prescriber.
- Bipolar masquerade. ~10% of “depression” turns out to be bipolar II. Microdosing can trigger mania. Screen.
- Placebo confusion. Mood is hard to self-rate. Without tracking (PHQ-9, partner check-ins, behavioral data) you cannot tell if anything is working.
- Substance reliance. Microdosing is not addiction-prone in the classical sense, but the daily ritual can become a crutch. Plan pauses.
Who should not pursue this
- Anyone in active suicidal crisis. Stabilize with standard care first.
- Anyone hoping to skip an SSRI/CBT trial entirely. They are evidence-based for good reason.
- Anyone unable to commit to objective tracking across 4-6 weeks.
- Anyone on lithium or MAOI.
Integration practices (Micro-Movement Method, depression-specific)
Depression collapses the body before it collapses the mood. Anhedonia, low motor activation, and shallow breath all precede the cognitive symptoms by hours or days. The Micro-Movement Method targets that somatic substrate directly: morning light, slow embodied warm-up, parasympathetic-leaning breath, and journaling that respects the low energy state rather than fighting it.
- Morning sun walk, before screens15 to 30 minutes outdoors within an hour of waking, no phone. Bright morning light anchors the circadian phase and lifts cortisol awakening response, both blunted in depression. This is non-negotiable on dose days.
- Slow Soma yoga warm-up against anhedonia10 to 20 minutes of floor-based, low-effort movement to bring proprioception back online before the day begins. The Micro-Movement Method emphasizes small, repeatable shapes that the body can complete even on low-energy mornings, which prevents the all-or-nothing collapse typical in depressive cycles. See our Soma yoga page.
- Breath-pacing 4 in, 6 out10 minutes daily. The longer exhale recruits parasympathetic tone (vagal efferent activity). Easier to sustain than 4-7-8 when motivation is low. See our breathwork resources.
- Journal toward small winsThree lines per evening: one thing the body did, one thing that registered as neutral or pleasant, one micro-intention for tomorrow. Avoid chasing big insight breakthroughs on microdose days. Depression integration compounds through small, repeated, embodied wins, not catharsis.
- Behavioral activation, body-firstSchedule one physical action per day before any cognitive task. Make tea, step outside, stretch. Motor activation precedes mood lift, not the other way around.
- Sleep architecture7-plus hours, fixed wake time, no caffeine after noon. Sleep is the single largest leverage point and is destroyed first in depressive cycles.
When to seek professional help
Active suicidality, plan, or means: 988 (US), findahelpline.com. ED for imminent risk. If your depression is unmanaged, see a clinician. Standard treatment is the floor, not optional.
